Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.

Effect of CYP3A422, CYP3A53, and CYP3A combined genotypes on tamoxifen metabolism.

http://www.wikidata.org/entity/Q38604479

about

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy

P2860

Q49554838-3ABEB0FC-DCEC-4E47-9BA2-40764C5DFBA9 Q58767256-6ED3B0C4-2E0B-4CA0-A6BA-A95E90821584

P2860

Effect of CYP3A422, CYP3A53, and CYP3A combined genotypes on tamoxifen metabolism.

Item

http://www.wikidata.org/entity/Q38604479

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.

@en

type

Item

label

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.

@en

prefLabel

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.

@en

P1476

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism

@en

P2093

A B Sanchez Spitman

http://www.w3.org/2001/XMLSchema#string

D J A R Moes

http://www.w3.org/2001/XMLSchema#string

H Gelderblom

http://www.w3.org/2001/XMLSchema#string

V O Dezentje

http://www.w3.org/2001/XMLSchema#string

P2860

Tamoxifen: catalyst for the change to targeted therapy

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

PharmGKB summary: tamoxifen pathway, pharmacokinetics

Tamoxifen ("Nolvadex"): a review.

Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response

P2888

s00228-017-2323-2

P304

1589-1598

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-017-2323-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Henk-Jan Guchelaar

Jesse J Swen

P577

2017-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091376975

http://www.w3.org/2001/XMLSchema#string

P698

28849250

http://www.w3.org/2001/XMLSchema#string

P932

5684327

http://www.w3.org/2001/XMLSchema#string

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.

about

P2860

P2860

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

Effect of CYP3A422, CYP3A53, and CYP3A combined genotypes on tamoxifen metabolism.

Effect of CYP3A422, CYP3A53, and CYP3A combined genotypes on tamoxifen metabolism.